Immunomonitoring measures in relapsing-remitting multiple sclerosis

被引:11
|
作者
Matsui, M [1 ]
Araya, S
Wang, HY
Matsushima, K
Saida, T
机构
[1] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Ctr, Ukyo Ku, Kyoto 6168255, Japan
[2] Natl Utano Hosp, Dept Neurol, Ukyo Ku, Kyoto 6168255, Japan
[3] Univ Tokyo, Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan
关键词
multiple sclerosis; flow cytometry; cytokine; surface antigen;
D O I
10.1016/j.jneuroim.2003.11.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared with stable stage patients and 16 healthy controls. CCR4(+) Th2 cells were persistently decreased at every MS stage as compared to the controls. CD4(+)CD29(+) and CD4(+)CXCR3(+) cells were closely correlated with IFN-gamma-producing cells. These findings suggest that simultaneous flow cytometry for these two types of measurements can provide information concerning current immune status in MS. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:192 / 199
页数:8
相关论文
共 50 条
  • [41] Therapeutic inertia in relapsing-remitting multiple sclerosis
    Rodrigues, R.
    Rocha, R.
    Bonifacio, G.
    Ferro, D.
    Sabenca, F.
    Goncalves, A. I.
    Correia, F.
    Pinheiro, J.
    Loureiro, J. L.
    Guerreiro, R. P.
    Vale, J.
    Sa, M. J.
    Costa, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 557 - 558
  • [42] Current management of relapsing-remitting multiple sclerosis
    Sedal, L.
    Wilson, I. B.
    McDonald, E. A.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 950 - 957
  • [43] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    [J]. NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [44] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [45] Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis
    Scott, Lesley J.
    [J]. DRUGS, 2019, 79 (08) : 875 - 886
  • [46] Mycophenolate mofetil for relapsing-remitting multiple sclerosis
    Xiao, Yousheng
    Huang, Jianyi
    Luo, Hongye
    Wang, Jin
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (02):
  • [47] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
  • [48] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    [J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19
  • [49] Disability trends and outcome measures in treatment trials of relapsing-remitting multiple sclerosis
    Blumhardt, L
    Liu, C
    [J]. ANNALS OF NEUROLOGY, 1999, 46 (03) : 502 - 502
  • [50] Predictors of driving in individuals with relapsing-remitting multiple sclerosis
    Akinwuntan, Abiodun Emmanuel
    Devos, Hannes
    Stepleman, Lara
    Casillas, Rhonda
    Rahn, Rebecca
    Smith, Suzanne
    Williams, Mitzi Joi
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (03) : 344 - 350